MedTrace Logo

Comparative Study Between Two Adjuvant Drugs to Bupivacaine for Post-operative Epidural Analgesia in Abdominal Surgeries

NCT05323214 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-07-15

No results posted yet for this study

Summary

Epidural analgesia is associated with early postoperative mobilization and rehabilitation with minimally associated pain and discomfort. Analgesic effect of local anesthetics is augmented by addition of adjuvants in epidural anesthesia ensuring satisfactory postoperative period. This study evaluates the effect of dexmedetomidine and fentanyl as additives to bupivacaine for epidural analgesia.

Conditions

  • Epidural Analgesia

Interventions

DRUG

Control Analgesic regimen

testing the efficiency of bupivacaine without adjuvant drugs in epidural analgesia

DRUG

Fentanyl Analgesic regimen

testing the efficiency of Fentanyl as an adjuvant drug to bupivacaine in epidural analgesia

DRUG

Dexmedetomidine Analgesic regimen

testing the efficiency of Dexmedetomidine as an adjuvant drug to bupivacaine in epidural analgesia

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Bahaa Eldin E Hassan, Professor · Department of Anesthesia, Intensive care and pain management, Ain Shams University.

  • Hadeel M Abd Elhamid, Professor · Department of Anesthesia, Intensive care and pain management, Ain Shams University.

  • Mohamed A Saleh, MD · Department of Anesthesia, Intensive care and pain management, Ain Shams University.

  • Ibrahim A Ibrahim, MD · Department of Anesthesia, Intensive care and pain management, Ain Shams University.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2022-08-31
Completion
2022-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05323214 on ClinicalTrials.gov